MAPK1 and non-small cell lung carcinoma: Our results revealed the mechanism of ADI in the treatment of NSCLC may be through the targets of AKT1, TP53, CASP3, MAPK1, and PTGS2, regulating the MAPK signaling pathway, PI3K-AKT signaling pathway, and TNF signaling pathway to exert its therapeutic effect.